mitoxantrone has been researched along with Heart Failure in 46 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography." | 9.12 | Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. ( Bernitsas, E; Mikol, DD; Wei, W, 2006) |
| "Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS)." | 8.90 | [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis]. ( Szwed, M, 2014) |
| "Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events." | 8.82 | Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 7.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS)." | 7.73 | Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. ( Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005) |
| "Mitoxantrone is an immunosuppressive drug usually delivered in severe relapsing remitting multiple sclerosis." | 7.72 | [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis]. ( Ali Chérif, A; Eusebio, A; Feuillet, L; Guedj, E; Malikova, I; Mundler, O; Pelletier, J, 2003) |
| "Fifteen women with metastatic breast cancer undergoing autologous bone marrow transplantation were treated with an intensive induction regimen including cyclophosphamide and mitoxantrone in a phase I-II study." | 7.68 | Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer. ( Hooker, JL; Lewkow, LM; Movahed, A, 1992) |
| "Thirty-four patients with advanced breast cancer, who had not received previous chemotherapy for metastatic disease, were treated with mitoxantrone 14 mg/m2 i." | 7.67 | Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. ( Coleman, RE; Knight, RK; Maisey, MN; Rubens, RD, 1984) |
| "Two children, who had received chemotherapy with doxorubicin and cisplatin for disseminated chondrosarcoma and recurrent rhabdomyosarcoma, developed congestive heart failure following treatment with mitoxantrone (DHAD); the total doses of DHAD were 128 and 90 mg/m2, respectively." | 7.66 | Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. ( Crom, DB; Miliauskas, J; Pratt, CB; Sanyal, SK; Sohlberg, K; Wallenberg, J, 1983) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 6.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Leukopenia is similar with the three drugs." | 6.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Half of our patients presenting with breast cancer will eventually require cytotoxic chemotherapy." | 6.65 | Mitoxantrone treatment in advanced breast cancer. ( Andrews, J; Cheng, ZM; Collins, J; Leyden, M; Russell, I; Sullivan, J, 1984) |
| "Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV study in which the safety of Mitoxantrone was monitored in a patient cohort from the United States (US)." | 5.17 | Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. ( Bock, D; Dangond, F; Jeffery, DR; Rivera, VM; Weinstock-Guttman, B, 2013) |
| "An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography." | 5.12 | Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. ( Bernitsas, E; Mikol, DD; Wei, W, 2006) |
| "Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS)." | 4.90 | [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis]. ( Szwed, M, 2014) |
| "Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events." | 4.82 | Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004) |
| "High-dose mitoxantrone therapy is associated with an excellent remission rate but with a significantly increased risk of clinical and subclinical early cardiotoxicity and heart failure." | 3.83 | Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis. ( Ahmed, M; Aurigemma, GP; Cerny, J; Escobar, J; Kane, JL; McGuiness, ME; McManus, DD; Meyer, TE; Nath, R; Ramanathan, M; Shaikh, AY; Shih, J; Suryadevara, S; Tighe, DA; Tripathi, A, 2016) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 3.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS)." | 3.73 | Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. ( Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005) |
| "Mitoxantrone is an immunosuppressive drug usually delivered in severe relapsing remitting multiple sclerosis." | 3.72 | [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis]. ( Ali Chérif, A; Eusebio, A; Feuillet, L; Guedj, E; Malikova, I; Mundler, O; Pelletier, J, 2003) |
| " Immunoblot analysis revealed iNOS protein expression in four out of six failing hearts from septic patients, whereas no iNOS-protein expression was detected in either non-failing human hearts (n = 6) or failing hearts due to IDC (n = 9), ischemic heart disease (IHD, n = 7), Becker muscular dystrophy (BMD, n = 2) and mitoxantrone-induced toxic cardiomyopathy TCM, n = 1)." | 3.69 | Expression of inducible nitric oxide synthase in failing and non-failing human heart. ( Bleese, NM; Förstermann, U; Nüssler, AK; Scholz, H; Stein, B; Thoenes, M; Tracey, WR, 1996) |
| "Fifteen women with metastatic breast cancer undergoing autologous bone marrow transplantation were treated with an intensive induction regimen including cyclophosphamide and mitoxantrone in a phase I-II study." | 3.68 | Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer. ( Hooker, JL; Lewkow, LM; Movahed, A, 1992) |
| "Thirty-four patients with advanced breast cancer, who had not received previous chemotherapy for metastatic disease, were treated with mitoxantrone 14 mg/m2 i." | 3.67 | Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. ( Coleman, RE; Knight, RK; Maisey, MN; Rubens, RD, 1984) |
| " Congestive heart failure resulting in death occurred in one case given 315mg /m2 of adriamycin and then 90 mg/m2 of mitoxantrone." | 3.67 | [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. ( Hattori, M; Honda, T; Sampi, K, 1984) |
| "Two children, who had received chemotherapy with doxorubicin and cisplatin for disseminated chondrosarcoma and recurrent rhabdomyosarcoma, developed congestive heart failure following treatment with mitoxantrone (DHAD); the total doses of DHAD were 128 and 90 mg/m2, respectively." | 3.66 | Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. ( Crom, DB; Miliauskas, J; Pratt, CB; Sanyal, SK; Sohlberg, K; Wallenberg, J, 1983) |
| "Mitoxantrone is an antineoplastic drug, recently approved for treatment of multiple sclerosis." | 2.72 | Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. ( Etemadifar, M; Hamzehloo, A, 2006) |
| "67 patients with relapsed or resistant multiple myeloma were randomized to receive either VAD (vincristine, doxorubicin, dexamethasone) or MOD (mitozantrone, vincristine, dexamethasone)." | 2.68 | A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. ( Cawley, JC; Davies, JM; Newland, AC; Pearce, R; Phillips, JK; Reilly, JT; Sherlaw-Johnson, C, 1995) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 2.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity." | 2.66 | Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985) |
| "Leukopenia is similar with the three drugs." | 2.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Half of our patients presenting with breast cancer will eventually require cytotoxic chemotherapy." | 2.65 | Mitoxantrone treatment in advanced breast cancer. ( Andrews, J; Cheng, ZM; Collins, J; Leyden, M; Russell, I; Sullivan, J, 1984) |
| "No patients experienced congestive heart failure (CHF) before treatment." | 2.41 | Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. ( Butine, MD; Edan, G; Eisenman, S; Ghalie, RG; Gonsette, RE; Goodkin, DE; Hartung, HP; Laurent, M; Mauch, E, 2002) |
| "Twelve years after the diagnosis of acute myeloid leukemia, and following a viral infection of an unknown cause, he developed symptoms of heart failure." | 1.36 | Heart transplant in a childhood leukemia survivor: a case report. ( Bubanska, E; Hrebik, M; Mladosievicova, B; Urbanova, D, 2010) |
| "However, cardiac failure, the primary cause of death in four patients, was associated with coagulative fiber necroses and contraction band necroses, which may be related to acute cyclophosphamide toxicity." | 1.27 | Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. ( Dörken, B; Körbling, M; Mall, G; von Herbay, A, 1988) |
| "Mitoxantrone is a synthetic anthraquinone that was developed through the doxorubicin analog program in hopes of retaining anticancer activity with less cardiotoxicity." | 1.27 | Cardiac evaluation of mitoxantrone. ( Balcerzak, SP; Bashore, TA; Neidhart, JA; Unverferth, BJ; Unverferth, DV, 1983) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| "All but one had breast cancer, 29 had received prior doxorubicin and 29 of the 37 patients who had not had prior doxorubicin received it or another anthracycline subsequently." | 1.27 | Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. ( Benjamin, RS; Carrasco, CH; Chawla, SP; Ewer, MS; Holmes, F; Mackay, B, 1985) |
| "Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were tested with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface area daily for 5 consecutive days every 4 weeks." | 1.26 | Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Schell, FC; Valdivieso, M; Yap, HY, 1981) |
| "Mitoxantrone is a promising new agent developed in an attempt to find drugs with a broad spectrum of antitumor activity and devoid of cardiotoxicity." | 1.26 | Potential cardiotoxicity with mitoxantrone. ( Blumenschein, G; Bodey, G; Schell, FC; Valdivieso, M; Yap, HY, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (39.13) | 18.7374 |
| 1990's | 10 (21.74) | 18.2507 |
| 2000's | 10 (21.74) | 29.6817 |
| 2010's | 8 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rivera, VM | 1 |
| Jeffery, DR | 1 |
| Weinstock-Guttman, B | 1 |
| Bock, D | 1 |
| Dangond, F | 1 |
| Szwed, M | 1 |
| Podlecka-Piętowska, A | 1 |
| Kochanowski, J | 1 |
| Zakrzewska-Pniewska, B | 1 |
| Opolski, G | 1 |
| Kwieciński, H | 1 |
| Kamińska, AM | 1 |
| Shaikh, AY | 1 |
| Suryadevara, S | 1 |
| Tripathi, A | 1 |
| Ahmed, M | 1 |
| Kane, JL | 1 |
| Escobar, J | 1 |
| Cerny, J | 1 |
| Nath, R | 1 |
| McManus, DD | 1 |
| Shih, J | 1 |
| McGuiness, ME | 1 |
| Tighe, DA | 1 |
| Meyer, TE | 1 |
| Ramanathan, M | 1 |
| Aurigemma, GP | 1 |
| Dörr, J | 2 |
| Bitsch, A | 1 |
| Schmailzl, KJ | 1 |
| Chan, A | 1 |
| von Ahsen, N | 1 |
| Hummel, M | 1 |
| Varon, R | 1 |
| Lill, CM | 1 |
| Vogel, HP | 1 |
| Zipp, F | 1 |
| Paul, F | 1 |
| Urbanova, D | 1 |
| Bubanska, E | 1 |
| Hrebik, M | 1 |
| Mladosievicova, B | 1 |
| Killestein, J | 1 |
| van der Meer, ML | 1 |
| Regelink, JC | 1 |
| Huijgens, PC | 1 |
| Polman, CH | 1 |
| Le Page, E | 1 |
| Leray, E | 1 |
| Edan, G | 2 |
| Staib, P | 1 |
| Forsch, S | 1 |
| Niedeggen, A | 1 |
| Janssens, U | 1 |
| Ghalie, RG | 1 |
| Laurent, M | 1 |
| Mauch, E | 1 |
| Eisenman, S | 1 |
| Hartung, HP | 1 |
| Gonsette, RE | 1 |
| Butine, MD | 1 |
| Goodkin, DE | 1 |
| Casarotto, D | 1 |
| Bottio, T | 1 |
| Gambino, A | 1 |
| Testolin, L | 1 |
| Gerosa, G | 1 |
| Gbadamosi, J | 1 |
| Münchau, A | 1 |
| Weiller, C | 1 |
| Schäfer, H | 1 |
| Feuillet, L | 1 |
| Guedj, E | 1 |
| Eusebio, A | 1 |
| Malikova, I | 1 |
| Pelletier, J | 1 |
| Mundler, O | 1 |
| Ali Chérif, A | 1 |
| Cohen, BA | 1 |
| Mikol, DD | 2 |
| Goffette, S | 1 |
| van Pesch, V | 1 |
| Vanoverschelde, JL | 1 |
| Morandini, E | 1 |
| Sindic, CJ | 1 |
| Bernitsas, E | 1 |
| Wei, W | 1 |
| Pratt, RG | 1 |
| Boehm, GA | 1 |
| Kortepeter, CM | 1 |
| Racoosin, JA | 1 |
| Hamzehloo, A | 1 |
| Etemadifar, M | 1 |
| Stuart-Harris, R | 1 |
| Pearson, M | 1 |
| Smith, IE | 2 |
| Olsen, EG | 1 |
| Sampi, K | 1 |
| Honda, T | 1 |
| Hattori, M | 1 |
| Crossley, RJ | 1 |
| Leyden, M | 1 |
| Cheng, ZM | 1 |
| Collins, J | 1 |
| Russell, I | 1 |
| Andrews, J | 1 |
| Sullivan, J | 1 |
| Coleman, RE | 1 |
| Maisey, MN | 1 |
| Knight, RK | 1 |
| Rubens, RD | 1 |
| Smalley, R | 1 |
| Gams, R | 1 |
| Pratt, CB | 1 |
| Crom, DB | 1 |
| Wallenberg, J | 1 |
| Sanyal, SK | 1 |
| Miliauskas, J | 1 |
| Sohlberg, K | 1 |
| Unverferth, DV | 1 |
| Unverferth, BJ | 1 |
| Balcerzak, SP | 2 |
| Bashore, TA | 1 |
| Neidhart, JA | 2 |
| Schell, FC | 2 |
| Yap, HY | 2 |
| Blumenschein, G | 1 |
| Valdivieso, M | 2 |
| Bodey, G | 1 |
| Blumenschein, GR | 2 |
| Buzdar, AU | 2 |
| Bodey, GP | 1 |
| Phillips, JK | 1 |
| Sherlaw-Johnson, C | 1 |
| Pearce, R | 1 |
| Davies, JM | 1 |
| Reilly, JT | 1 |
| Newland, AC | 1 |
| Cawley, JC | 1 |
| Benjamin, RS | 2 |
| Bezwoda, WR | 1 |
| Bezwoda, MA | 1 |
| Seymour, L | 1 |
| Dansey, R | 1 |
| Ariad, S | 1 |
| Okamoto, M | 1 |
| Miyazaki, H | 1 |
| Tsuzuki, M | 1 |
| Ino, T | 1 |
| Ezaki, K | 1 |
| Hirano, M | 1 |
| Thoenes, M | 1 |
| Förstermann, U | 1 |
| Tracey, WR | 1 |
| Bleese, NM | 1 |
| Nüssler, AK | 1 |
| Scholz, H | 1 |
| Stein, B | 1 |
| Kahles, H | 1 |
| Bastian, HJ | 1 |
| Schiffmann, O | 1 |
| Geck, M | 1 |
| Helmke, FR | 1 |
| Golz, N | 1 |
| Aitini, E | 1 |
| Cavazzini, G | 1 |
| Cantore, M | 1 |
| Rabbi, C | 1 |
| Rivera, A | 1 |
| Togliani, B | 1 |
| Di Marco, A | 1 |
| Smerieri, F | 1 |
| Lewkow, LM | 1 |
| Hooker, JL | 1 |
| Movahed, A | 1 |
| Carrió, I | 1 |
| Estorch, M | 1 |
| Berná, L | 1 |
| Germá, JR | 1 |
| Alonso, C | 1 |
| Ojeda, B | 1 |
| de Andrés, L | 1 |
| Lopez-Pousa, A | 1 |
| Martinez-Duncker, C | 1 |
| Torres, G | 1 |
| Ellis, ED | 1 |
| Williams, SF | 1 |
| Moormeier, JA | 1 |
| Kaminer, LS | 1 |
| Bitran, JD | 1 |
| Janmohammed, R | 1 |
| Milligan, DW | 1 |
| von Herbay, A | 1 |
| Dörken, B | 1 |
| Mall, G | 1 |
| Körbling, M | 1 |
| Bull, FE | 1 |
| Von Hoff, DD | 2 |
| Stephens, RL | 1 |
| Panettiere, FJ | 1 |
| Posner, LE | 1 |
| Dukart, G | 1 |
| Goldberg, J | 1 |
| Bernstein, T | 1 |
| Cartwright, K | 1 |
| Cowan, JD | 1 |
| Osborne, CK | 1 |
| Constanzi, JJ | 1 |
| Vaughn, CB | 1 |
| Marcus, C | 1 |
| Smith, TL | 1 |
| Chawla, SP | 1 |
| Ewer, MS | 1 |
| Carrasco, CH | 1 |
| Mackay, B | 1 |
| Holmes, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)[NCT01627938] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for mitoxantrone and Heart Failure
| Article | Year |
|---|---|
[Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Axons; Cell Death; Heart Failure; Humans; Mitoxantrone | 2014 |
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.
Topics: Adolescent; Adult; Age Factors; Aged; Chi-Square Distribution; Confidence Intervals; Drug Administra | 2002 |
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Topics: Animals; Cardiomyopathies; Drug Monitoring; Heart Failure; Humans; Immunosuppressive Agents; Leukemi | 2004 |
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1983 |
Rationale for the use of mitoxantrone in the older patient: cardiac toxicity.
Topics: Age Factors; Aged; Biopsy; Breast Neoplasms; Doxorubicin; Heart Failure; Humans; Mitoxantrone; Myoca | 1995 |
13 trials available for mitoxantrone and Heart Failure
| Article | Year |
|---|---|
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Topics: Adult; Aged; Female; Heart Failure; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Scle | 2013 |
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
Topics: Adult; Animals; Antineoplastic Agents; Cardiovascular Agents; Female; Heart Failure; Humans; Male; M | 2006 |
Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Topics: Adult; Antineoplastic Agents; Dose-Response Relationship, Drug; Echocardiography; Electrocardiograph | 2006 |
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1983 |
Clinical safety and tolerance of mitoxantrone (Novantrone).
Topics: Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Depr | 1983 |
Mitoxantrone treatment in advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Female; Heart Failure; Huma | 1984 |
A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance; F | 1995 |
NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Heart Failure; Humans; Lymphoma, | 1993 |
A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1992 |
A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies.
Topics: Actuarial Analysis; Chicago; Cyclophosphamide; Drug Evaluation; Heart Failure; Hematopoietic Stem Ce | 1990 |
Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as T | 1985 |
Mitoxantrone: an overview of safety and toxicity.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini | 1985 |
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica | 1985 |
29 other studies available for mitoxantrone and Heart Failure
| Article | Year |
|---|---|
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Topics: Adult; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Female; Heart Diseases; Heart Failure; H | 2014 |
Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis.
Topics: Aged; Antineoplastic Agents; Causality; Comorbidity; Echocardiography; Elasticity Imaging Techniques | 2016 |
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tr | 2009 |
Heart transplant in a childhood leukemia survivor: a case report.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Daunorubicin; Heart F | 2010 |
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Topics: Antineoplastic Agents; Female; Heart Failure; Humans; Middle Aged; Mitoxantrone; Multiple Sclerosis; | 2010 |
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Topics: Adult; Amenorrhea; Female; France; Heart Failure; Humans; Immunologic Factors; Leukemia; Male; Middl | 2011 |
[Percutaneous coronary intervention in a patient with acute myeloid leukemia].
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; | 2012 |
The last to die is hope: prolonged mechanical circulatory support with a Novacor left ventricular assist device as a bridge to transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cardiomyopathy, Dilated; Castleman Di | 2003 |
Severe heart failure in a young multiple sclerosis patient.
Topics: Adult; Antineoplastic Agents; Drug Overdose; Heart Failure; Humans; Male; Mitoxantrone; Multiple Scl | 2003 |
[Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
Topics: Acute Disease; Female; Heart Failure; Humans; Middle Aged; Mitoxantrone; Multiple Sclerosis | 2003 |
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Mitoxant | 2005 |
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Topics: Analgesics; Cardiomyopathies; Dose-Response Relationship, Drug; Drug-Related Side Effects and Advers | 2005 |
Cardiotoxicity associated with mitoxantrone.
Topics: Anthraquinones; Antineoplastic Agents; Heart Failure; Humans; Mitoxantrone | 1984 |
[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1984 |
Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Heart | 1984 |
Phase II study of mitoxantrone in patients with metastatic breast carcinoma: a Southeastern Cancer Study Group project.
Topics: Adult; Anthraquinones; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; | 1983 |
Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.
Topics: Anthraquinones; Child; Child, Preschool; Chondrosarcoma; Cisplatin; Doxorubicin; Female; Heart; Hear | 1983 |
Cardiac evaluation of mitoxantrone.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Biopsy; Female; Heart Failure; Heart Function Tests; Hu | 1983 |
Potential cardiotoxicity with mitoxantrone.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Heart | 1982 |
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Agranulocytosis; Anthracenes; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Dru | 1981 |
[Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].
Topics: Aclarubicin; Adrenergic beta-Antagonists; Adult; Antibiotics, Antineoplastic; Cardiomyopathy, Hypert | 1995 |
Expression of inducible nitric oxide synthase in failing and non-failing human heart.
Topics: Animals; Cardiomyopathies; Cardiomyopathy, Dilated; Cell Line; Cyclic GMP; Gene Expression; Heart Fa | 1996 |
[Mitoxantrone-induced acute left heart failure after intrapleural administration].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Dose-R | 1997 |
Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1992 |
Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Female; Heart; Heart Failure; Humans; Indium Radioisotop | 1991 |
Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Female; Heart Failure; Humans; Leukemia, | 1989 |
Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Cardiomyopat | 1988 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |
Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.
Topics: Adult; Aged; Angiocardiography; Anthraquinones; Antineoplastic Agents; Biopsy; Breast Neoplasms; Dox | 1985 |